Natixis Advisors, L.P. Catalyst Pharmaceuticals, Inc. Transaction History
Natixis Advisors, L.P.
- $54.1 Billion
- Q1 2025
A detailed history of Natixis Advisors, L.P. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 62,990 shares of CPRX stock, worth $1.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
62,990
Previous 59,253
6.31%
Holding current value
$1.6 Million
Previous $1.24 Million
23.52%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CPRX
# of Institutions
389Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$474 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$215 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$140 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$86.8 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$79.5 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.61B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...